EP2098526A1 - Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques - Google Patents

Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques Download PDF

Info

Publication number: EP2098526A1
Authority: EP; European Patent Office
Prior art keywords: pyrazin; hexahydropyrrolo; alkyl; formula; compound
Prior art date: 2008-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP08101879A

Other languages

German (de)

English (en)

Other versions

EP2098526B1 (fr

Inventor

Carla Ghelardini

Marisa Martinelli

Carlo Parini

Silvano Ronzoni

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neurotune AG

Original Assignee

Neurotune AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-22

Filing date

2008-02-22

Publication date

2009-09-09

2008-02-22 Priority to ES08101879.8T priority Critical patent/ES2454366T3/es

2008-02-22 Application filed by Neurotune AG filed Critical Neurotune AG

2008-02-22 Priority to PL08101879T priority patent/PL2098526T3/pl

2008-02-22 Priority to EP08101879.8A priority patent/EP2098526B1/fr

2009-02-17 Priority to CA2716230A priority patent/CA2716230C/fr

2009-02-17 Priority to AU2009217201A priority patent/AU2009217201B2/en

2009-02-17 Priority to MX2010009228A priority patent/MX2010009228A/es

2009-02-17 Priority to US12/918,718 priority patent/US8334286B2/en

2009-02-17 Priority to EA201001344A priority patent/EA017737B1/ru

2009-02-17 Priority to JP2010547016A priority patent/JP5400804B2/ja

2009-02-17 Priority to CN200980105813.4A priority patent/CN101945876B/zh

2009-02-17 Priority to PCT/CH2009/000064 priority patent/WO2009103176A1/fr

2009-02-17 Priority to BRPI0908495A priority patent/BRPI0908495A2/pt

2009-02-20 Priority to CL2009000388A priority patent/CL2009000388A1/es

2009-02-20 Priority to ARP090100617A priority patent/AR070465A1/es

2009-02-23 Priority to PE2009000262A priority patent/PE20091398A1/es

2009-09-09 Publication of EP2098526A1 publication Critical patent/EP2098526A1/fr

2010-08-10 Priority to ZA2010/05704A priority patent/ZA201005704B/en

2010-08-18 Priority to IL207669A priority patent/IL207669A/en

2014-01-15 Application granted granted Critical

2014-01-15 Publication of EP2098526B1 publication Critical patent/EP2098526B1/fr

Status Active legal-status Critical Current

2028-02-22 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Definitions

the present invention relates to nitrogen-containing bicyclic compounds, a process for their preparation, pharmaceutical compositions containing them, and their use in medicine.
Chronic pain may be divided in two main categories: chronic inflammatory pain and neuropathic pain.
the latter is due to a direct lesion on the nervous pathways by the noxa, which can be infectious, metabolic, vascular or other.
the lesioned tissues release algogenic factors which in turn damage nervous terminals creating a vicious mechanism which maintains and potentiates the perception of pain.
Chronic pain of both neuropathic and inflammatory origin, is an important epidemiologic aspect of a high unmet medical need condition, i.e. of a therapeutic area which at present needs remarkable improvements since poorly effective treatments and a plethora of important noxious side-effects are present.
Nucleoside analog reverse transcriptase inhibitors are commonly used as antiviral drugs in the treatment of AIDS. These drugs often cause the insurgence of peripheral neuropathies with different degrees of severity after prolonged treatment. As in the case of chemotherapeutic agents, these symptoms may be so strong to induce shortening or suspension of these life-saving therapies.
the patterns of these neuropathies are clearly different from those induced by the progression of AIDS; they are in fact characterized by the sudden onset of very intense burning discomfort in both hands and feet at about the tenth week of treatment. HIV-induced neuropathies, on the contrary, have a very slow progression ( Dubinsky R.M. 1989, Muscle Nerve 12:856-860 ).
neuropathic pain may be caused by viral infections.
Postherpetic neuralgia for instance, is caused by the reactivation, long after the infection, of the varicella-zoster virus.
This kind of neuropathy is characterized by the development of strong mechanical allodynia, frequent loss of sensitivity towards thermal stimuli and spontaneous intermittent pain. The severity of pain may compromise the quality of life of patients suffering from this condition.
Cephalea is a kind of chronic pain of high epidemiologic relevance. When cephalea occurs in a paroxystic way, with recurrent episodes lasting from hours to days and is associated to general sickness, it is called hemicrania.
hemicrania entails the use of different kind of analgesic agents, from non-steroidal anti-inflammatory drugs (NSAIDs) to opioids, antihistaminic drugs and ergotamine derivatives.
NSAIDs non-steroidal anti-inflammatory drugs
triptan 5HT2 antagonists have been used; they are often able to block an attack at its insurgence, if promptly administered. All these methods show serious limits in terms of both efficacy and toxicity.
NSAIDs non-steroidal anti-inflammatory drugs
5HT2 antagonists In the most severe cases, in which painful attacks recur many times a week, a pre-emptive therapy with antiepileptic, beta blocker and antidepressant drugs is performed. The maximum result which can be achieved with these pre-emptive therapies is 50% reduction in the frequency and intensity of the painful attacks, but not their definitive remission.
Inflammatory pain is another form of chronic pain. It is caused by the release of mediators which either directly activate the nociceptors localized on primary afferents or lower their activation threshold, thus increasing their sensitivity to either painful or non-painful stimuli of different nature. Excited primary afferents may in turn release neurotransmitters which can stimulate immune cells recruited by the inflammatory process causing the release of additional inflammatory mediators.
Osteoarthritis is a particularly severe and painful form of this kind of pathology. Osteoarthritis is a form of degenerative arthritis causing the breakdown and eventual loss of the cartilage of one or more joints. The most common symptom related to this pathology is pain in the affected joint, which increases in proportion to the amount of use of the joint. As the disease progresses there is pain at rest and later nocturnal pain.
the present invention refers to compounds of general formula (I) wherein:
a large part of the compounds of formula (I) are new compounds: they represent per se a further object of the invention.
the invention further includes a process for synthesizing these compounds and pharmaceutical composition for their administration to a patient.
alkyl groups can be indifferently linear or branched; said alkyl groups are preferably C 1-4 alkyl groups, more preferably methyl or ethyl. All "aryl” groups are preferably C 5-10 aryl groups, in particular phenyl and naphthyl.
heterocycle means saturated and unsaturated, single or fused heterocyclic rings, and comprising up to four heteroatoms, chosen among oxygen, sulphur and nitrogen.
All alkyl, aryl or heterocyclic groups may be optionally substituted one or more times by e.g. halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, aminoC 1-6 alkyl, (C 1-6 alkyl)aminoC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, carboxy, cyano or perhaloC 1-6 alkyl.
halogen C 1-6 alkyl, C 1-6 alkoxy, hydroxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, aminoC 1-6 alkyl, (C 1-6 alkyl)aminoC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, carboxy, cyano or perhaloC 1-6 alkyl.
the R groups shown in formula (I) may be attached at any position of the rings upon which they are drawn: thus the upper drawn ring contains one R group, and the lower drawn ring contains two R groups, with all R being independently chosen among the above defined meanings.
the two R groups may be attached to different ring members, as well as to the same ring member: in the latter case, where both R represent an identical C 1-6 alkyl, they form a geminal substituent, e.g. gem-dimethyl.
R is H or C 1-4 alkyl; more preferably, R is H, methyl or ethyl; even more preferably, R is H.
A is aryl, 2-pyridyl, 3-pyridyl, 4-pyridyl; more preferably, A is aryl substituted with halogen, cyano, trifluoromethyl, methyl; even more preferably, A is 2-fluorophenyl and 3-fluorophenyl.
the compounds of formula (I) can exhibit stereoisomerism because of the presence of chiral atoms and/or multiple bonds.
the present invention therefore extends to stereoisomers of the compounds of formula (I), including racemates and mixtures where the enantiomers are present in any proportions, enantiomers, diastereoisomers and geometric isomers.
the subject invention also includes isotopically-labelled compounds, which are identical to those recited in formula (I) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
isotopes that can be incorporated into compounds of the invention and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I and 125 I.
the compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention.
Isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
11 C and 18 F isotopes are particularly useful in PET (positron emission tomography), and 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
substitution with heavier isotopes such as deuterium, i.e., 2 H can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
Isotopically labelled compounds of formula (I) and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
the compounds of formula (I) are new compounds, with the exceptions specified below.
the new compounds represent per se a further embodiment of the present invention and are included as such within its scope.
the new compounds are described by formula (I) as above defined, with the proviso that:
the compounds disclaimed by (i) are known from EP-A-1118612 ; those disclaimed by (ii) and (iii) are known from Bioorg.Med.Chem.,12(2004), 71-85 .
the present invention also provides processes for preparing the compounds of formula (I).
a compound of formula (II) is dissolved in a suitable solvent, such as e.g. dichloromethane, acetonitrile, dimethylformamide or mixtures thereof, in the presence of a suitable organic or inorganic base, such as e.g. triethylamine or potassium carbonate, then a solution of a compound of formula (III) in a suitable solvent, such as e.g. dichloromethane, acetonitrile, dimethylformamide or mixtures thereof, is added to the preceding reaction mixture at a suitable temperature, typically between 0°C and ambient temperature.
a suitable solvent such as e.g. dichloromethane, acetonitrile, dimethylformamide or mixtures thereof
the solvent is evaporated, the residue is taken up with water and a suitable solvent, such as for example ethyl acetate or dichloromethane.
a suitable solvent such as for example ethyl acetate or dichloromethane.
the organic phase is collected, dried with, for example, sodium sulfate and the solvent is removed by evaporation.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC.
formula (Ib) The compounds of formula (I) in which X is a bond, hereinafter referred as formula (Ib), can be prepared according to Scheme 2, reacting a compound of formula (II) with a compound of formula (IV), where R, Y, m, n and A are as defined for formula (I) and W is as defined above.
a compound of formula (II) is dissolved in a suitable solvent, such as e.g. dimethylformamide, then a compound of formula (IV) is added, together with Cul and a suitable base, such as for example potassium carbonate and the resulting mixture is stirred at a suitable temperature, typically between room temperature and reflux temperature, for a suitable time, typically between 1 and 16 hours.
a suitable solvent such as, for example, ethyl acetate
the residual solids are filtered off, the organic solution is washed with water or a saturated aqueous sodium chloride solution, then it is dried with, for example, sodium sulfate and the solvent is evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC.
formula (IIa) The compounds of formula (II) in which n is 0, Y is CH 2 and R and m are as defined for formula (I), hereinafter referred as formula (IIa) can be prepared according to the reaction sequence illustrated in Scheme 4, in which a compound of formula (VI) is converted in the corresponding methanesulfonate (VII) (step A), which is then reacted in step B with a compound of formula (VIII) to give a compound of formula (IX), which is in turn converted into the corresponding methanesulfonate (X) in step C and cyclised to compound (XI) in step D. Finally, debenzylation in step E yields compounds of formula (IIa).
Step A is typically conducted dissolving a compound of formula (VI) in a suitable solvent such as e.g. ethanol-free chloroform, then adding at a suitable temperature, typically between 0°C and room temperature, a suitable base such as triethylamine, followed by methanesulfonyl chloride, stirring the reaction mixture for a suitable period of time, typically between 1 and 12 h, at a suitable temperature, typically between 0°C and room temperature.
the reaction mixture is then diluted with a suitable solvent, such as for example dichloromethane, and washed with an aqueous solution of a suitable base, such as a saturated aqueous solution of sodium bicarbonate.
the organic solution is then dried with for example sodium sulfate and evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (VII) to be processed in step B.
Step B is typically performed by heating a compound of formula (VII) with a compound of formula (VIII) in a microwave oven at a suitable temperature, typically between 50°C and 150°C, preferably at 130°C, for a suitable period of time, typically between 10 and 60 minutes, preferably 40-45 minutes, then partitioning the residue between water and a suitable solvent such as dichloromethane, washing the organic phase with a saturated sodium chloride solution, drying it over e.g. sodium sulfate and evaporating the solvent.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (IX) to be processed in step C.
Step C can be carried out following the conditions reported above for step A, yielding a compound of formula (X) to be processed in step D.
Step D is typically carried out by dissolving a compound of formula (X) in a suitable solvent, such as e.g. acetonitrile or tetrahydrofuran or mixtures thereof, then adding a suitable base such as, for example, sodium hydride, at a suitable temperature, typically between 0°C and room temperature. After stirring at a suitable temperature, typically between 0°C and room temperature, for a suitable time, typically between 1 and 24 hours, preferably between 4 and 16 hours, the solvent is removed and the residue is taken up with water and extracted with a suitable solvent, such as dichloromethane or ethyl acetate.
a suitable solvent such as e.g. acetonitrile or tetrahydrofuran or mixtures thereof.
the organic phase may be washed with a saturated sodium chloride solution, then it is dried with, for example, sodium sulfate and then evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (XI) to be processed in step E.
Step E is a typical debenzylation reaction, which can be performed e.g. in phase-transfer conditions, dissolving a compound of formula (XI) in a suitable solvent such as an alcohol, e.g. methanol, adding a suitable hydrogen source such as ammonium formate, followed by a suitable catalyst, such as palladium on carbon, and then heating the reaction mixture at a suitable temperature, typically reflux temperature, for a suitable time, typically between 1 and 8 hours, preferably between 2 and 3 hours. The catalyst is filtered off and the solvent evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (IIa).
formula (IIb) The compounds of formula (II) in which n is 1, Y is CH 2 and R and m are as defined for formula (I), hereinafter referred as formula (IIb), may be prepared as described in Scheme 5, in which a compound of formula (XII) is reacted in step F with a compound of formula (XIII), where R, W and Q are as defined above, to give a compound of formula (XIV) which is converted in step G into a compound of formula (IIb).
Step F may be typically performed dissolving a compound of formula (XII) in a suitable solvent such as tetrahydrofuran, and then adding this solution to a solution of a suitable base in a suitable solvent, such as a solution of lithium diisopropylamide in tetrahydrofuran, under an inert atmosphere, such as a nitrogen or argon atmosphere, at a suitable temperature, typically between -78°C and -20°C.
a suitable solvent such as tetrahydrofuran
a solution of a compound of formula (XIII) in a suitable solvent such as tetrahydrofuran is added to the preceding solution and stirring is continued for a suitable time, typically between 2 and 20 hours, at a suitable temperature, typically between -78°C and room temperature; the reaction is then quenched with e.g. a saturated ammonium chloride solution, then it is extracted with a suitable solvent, such as ethyl acetate. The organic phase is dried with e.g. sodium sulfate and the solvent is evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (XIV) to be processed in step G.
Step G is a typical hydrogenation reaction, which can be conducted dissolving a compound of formula (XIV) in a suitable solvent such as ethanol, then adding a suitable catalyst such as palladium on carbon, and then hydrogenating the reaction mixture at a suitable hydrogen pressure, typically between 20 and 50 psi, for a suitable period of time, typically between 1 and 24 hours.
a suitable hydrogen pressure typically between 20 and 50 psi
the catalyst is filtered off, the solvent is evaporated and the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (IIb).
Step H is a typical esterification reaction, which may be performed for example dissolving the compound of formula (XV) in a suitable alcoholic solvent of formula Q-OH, e.g. methanol or ethanol, then adding an acidic cation exchange resin (e.g. Amberlyst® 15) and stirring the resulting mixture for a suitable time, typically between 1 and 24 hours, at a suitable temperature, typically between room and reflux temperature; after filtering off the insoluble materials and evaporating the solvent, a compound of formula (XVI) is obtained, which may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, before being processed in step I.
a suitable alcoholic solvent of formula Q-OH e.g. methanol or ethanol
an acidic cation exchange resin e.g. Amberlyst® 15
a compound of formula (XVI) is obtained, which may be purified, if necessary, by conventional purification methods such as flash
Step I is typically performed dissolving a compound of formula (XVI) in a suitable solvent, such as for example acetonitrile, then adding a suitable base such as, e.g., sodium hydride, at a suitable temperature, typically between -10°C and room temperature, then after stirring for a suitable time, typically between 15 min and 2 hours, a solution of a compound of formula (XVII) in a suitable solvent such as acetonitrile, is added to the preceding reaction mixture and stirring is continued for a suitable period of time, typically between 1 and 24 hours, at a suitable temperature, typically between -10°C and room temperature.
a suitable solvent such as for example acetonitrile
the solvent is evaporated, the residue is partitioned between water and a suitable solvent such as, e.g., ethyl acetate, the organic phase is dried with e.g. sodium sulfate and evaporated.
a suitable solvent such as, e.g., ethyl acetate
the organic phase is dried with e.g. sodium sulfate and evaporated.
the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (XVIII) to be processed in step J.
Step J is a typical hydrogenation reaction, which can be performed by dissolving the compound of formula (XVIII) in a suitable solvent, such as e.g. methanol, then adding a suitable catalyst such as platinum oxide, an hydrogenating the resulting reaction mixture at a suitable hydrogen pressure, typically between 20 and 50 psi, for a suitable time, typically between 1 and 24 hours. After filtering off the catalyst and evaporating the solvent, the crude product may be purified, if necessary, by conventional purification methods such as flash chromatography, trituration, crystallization or preparative HPLC, yielding a compound of formula (IIc).
a suitable solvent such as e.g. methanol
a suitable catalyst such as platinum oxide
the compounds of formula (V) may be prepared as described e.g. in US Patent 3225077 .
the compounds of formula (I) can be used in the treatment of any chronic pain conditions, particularly those of neuropathic or inflammatory origin; chronic pain may be originated e.g. by neuropathies deriving from nerve injury or compression, diabetic polineuropathies, post-herpetic neuralgia, or may be the side effect of treatments with other drugs.
chronic pain-causing treatments are those with chemotherapeutic agents (where the chemotherapeutic agent is e.g. taxol and derivatives thereof, cisplatin, oxaliplatin or vinca alkaloids in oncological patients), antibacterial agents (such as e.g.
metronidazole or isoniazid include antiviral agents (particularly nucleoside reverse transcriptase inhibitors, e.g. ddC, d4T or AZT in HIV-patients).
antiviral agents particularly nucleoside reverse transcriptase inhibitors, e.g. ddC, d4T or AZT in HIV-patients.
Other examples of chronic pain conditions treatable with the invention are those associated to osteoarthritis, phantom limb, multiple sclerosis or other inflammatory autoimmune diseases, neuropathies, fibromyalgia, carpal and tarsal tunnel syndromes, headache, migraine and complex regional pain syndromes (CRPS).
CRPS complex regional pain syndromes
the compounds of the invention are also useful for the treatment of epilepsy and dyskinesias associated with the treatment of Parkinson's disease with L-DOPA.
the compounds of formula (I) may be administered as such or in association with any other active principle useful for the treatment or prevention of the above mentioned diseases.
Non-limiting examples of other active principles to be used in association with compounds of the invention are e.g. gabapentin or pregabalin for the treatment of chronic pain.
the compound of formula (I) can also be used in advance to a chemotherapeutic treatment, so as to prevent the development of chronic pain.
the treatment with compound of the invention is started before the chemotherapeutic treatment and possibly continues jointly therewith.
the compounds of formula (I) are also useful in treating possible chemotherapy-induced peripheral neurotoxicity (CIPN) symptoms developing after conclusion of the treatment with chemotherapeutic drugs; in this case the treatment with compounds of formula (I) is started (or continued) after conclusion of the chemotherapeutic treatment.
CIPN chemotherapy-induced peripheral neurotoxicity
the compounds of formula (I) can be prepared in the forms of salts or hydrates.
Suitable salts are pharmaceutically acceptable salts.
Suitable hydrates are pharmaceutically acceptable hydrates.
the therapeutic regimen for the different clinical syndromes must be adapted to the type and seriousness of the pathology or pathologies to be treated, taking into account also the route of administration, the form in which the compound is administered and the age, weight and conditions of the subject involved.
the compounds of the invention can be administered at doses ranging e.g. from about 10 to about 1500 mg/day.
the invention encompasses pharmaceutical compositions of compounds of formula (I) useful for the above mentioned treatments.
the amounts of the active principle, expressed in mg/day, are those cited above
Compounds of the invention may be pharmaceutically formulated according to known methodologies.
the various pharmaceutical compositions may be selected according to the needs of the treatment.
compositions can be prepared by mixing and can be suitably adapted for oral or parenteral administration, and as such, can be administered in the form of tablets, capsules, oral preparations, powders, granules, pellets, liquid solutions for injection or infusion, suspensions or suppositories.
Tablets and capsules for oral administration are usually supplied in dosage units and may contain conventional excipients such as binders, fillers, diluents, tabletting agents, lubricants, detergents, disintegrants, colorants, flavors and wetting agents. Tablets may be coated in accordance to methods well known in the art.
Suitable fillers include for example cellulose, mannitol, lactose and similar agents.
Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate.
Suitable lubricants include, for example, magnesium stearate.
Suitable wetting agents include for example sodium lauryl sulfate.
These solid oral compositions can be prepared with conventional mixing, filling or tabletting methods.
the mixing operations can be repeated to disperse the active agent in compositions containing large quantities of fillers. These operations are conventional.
the oral liquid compositions can be provided in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or in the form of a dry product to be reconstituted with water or with a suitable liquid carrier at the time of use.
the liquid compositions can contain conventional additives such as suspending agents, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non aqueous carriers (which can include edible oil) for example almond oil, fractionated coconut oil, oily esters such a glycerin esters, propylene glycol or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid and if desired, conventional flavours or colorants.
Oral formulations also include conventional sustained release formulations, such as tablets or granules with enteric coating.
fluid dosage units can be prepared containing the active compounds and a sterile carrier.
the active compounds depending on the carrier and concentration, can be suspended or dissolved.
the parenteral solutions are normally prepared by dissolving the compound in a carrier and sterilizing by filtration, before filling suitable vials or ampoules and sealing.
Adjuvants such as local anaesthetics, preservatives and buffering agents can be advantageously dissolved in the carrier.
the composition can be frozen after filling the vial and the water removed under vacuum.
parenteral suspensions are prepared essentially in the same way, with the difference that the active compounds can be suspended rather than dissolved in the carrier, and can be sterilized by exposure to ethylene oxide prior to being suspended in the sterile carrier.
a surfactant or humectant can be advantageously included to facilitate uniform distribution of the compound of the invention.
Topic formulations may contain for example ointments, creams, lotions, gels, solutions, pastes and/or may contain liposomes, micelles and/or microspheres.
transdermal delivery A further method of administration for the compounds of the invention is transdermal delivery.
Typical transdermal formulations include conventional aqueous and non-aqueous vectors, such as creams, oil, lotions or pastes or may be in the form of membranes or medicated patches.
compositions are normally accompanied by written or printed instructions, for use in the treatment concerned.
Methanesulfonic acid 2-[benzyl-((S)-5-oxo-pyrrolidin-2-ylmethyl)-amino]-ethyl ester (2.9 g, 8.89 mmol) was dissolved in a mixture of CH 3 CN/THF (1/1, 40 ml) and then 60% NaH (462 mg, 11.56 mmol) was added portionwise at room temperature, under a nitrogen atmosphere. After stirring for 16 hours, the solvent was removed under vacuum and the residue was taken up with water and extracted with DCM. The organic phase was washed with brine, dried (Na 2 SO 4 ) and evaporated under vacuum.
Methanesulfonic acid 2-[benzyl-((R)-5-oxo-pyrrolidin-2-ylmethyl)-amino]-ethyl ester (3.5 g, 10.74 mmol) was dissolved in CH 3 CN (20 ml) and then 60% NaH (558 mg, 13.96 mmol) was added portionwise at room temperature. After stirring for 4 hours, the solvent was removed under vacuum and the residue was treated with water and extracted with ethyl acetate. The organic phase was washed with brine, dried (Na 2 SO 4 ) and evaporated under vacuum.
Butyllithium (1.6 M in hexane solution, 10 ml, 16 mmol) was added dropwise to a solution of diisopropylamine (2.25 ml, 16 mmol) in anhydrous THF (50 ml) at -20°C under a nitrogen atmosphere. The mixture was stirred at -20°C for 30 minutes and after cooling at -70°C a solution of 2-methyl-pyrazine (1.47 ml, 16 mmol) in THF (10 ml) was added dropwise.
paw mechanical sensitivity was determined using either the paw pressure test or the incapacitance test.
the paw pressure test utilizes a Randall & Selitto apparatus, exerting a force that increases at constant rate (32 g/s).
the stimulus at which rats withdrawn the paw was evaluated before and at different times after treatment.
Results represent the mean of mechanical thresholds expressed as grams. To avoid any possible damage to the animal paw the maximum applied force was fixed at 240 g.
the incapacitance test utilizes an incapacitance tester that provides an automatic assessment of anti-hyperalgesic potency by measuring the weight distribution on the two hind paws of tested animal The force exerted by each limb (measured in grams) is averaged over a user selectable period thus indicating any tendency for the animal to shift its weight from one side to another, hence providing a quantitative measurement of incapacitance.
Peripheral neuropathy is induced by repeated administration of vincristine, paclitaxel or oxaliplatin to adult male Sprague-Dawley rats (150-200 g, supplier Harlan).
Osteoarthritis was induced by a single administration of 2 mg (in a volume of 25 ⁇ l) of monosodium iodoacetate (MIA) into the left knee joint of anaesthetized rats (male adult Sprague Dawley rats, 150-200 g, supplier Harlan) ( Fernihough J. 2004, Pain 112:83-93 ). This treatment induces the progressive degeneration of the joint and the development of hyperalgesia, mimicking at the histological and behavioral levels what observed in humans. Pharmacological test was performed 7 days after treatment.
MIA monosodium iodoacetate
pancreatic toxin streptozotocin induces both mechanical and thermal hyperalgesia, possibly by mimicking diabetic neuropathy.
Rats male adult Sprague Dawley rats, 150-200 g, supplier Harlan) were injected intraperitoneally with 50 mg/kg of STZ and 21 days after toxin treatment were tested for mechanical hyperalgesia in the paw pressure test.
Rats Male adult Sprague Dawley rats, 150-200 g, supplier Harlan were injected i.p. with 200 ug/kg of RTX and after 3 weeks were tested for mechanical hyperalgesia in the paw pressure test.
Results represent the mean ⁇ S.E.M. of mechanical thresholds expressed as grams. Each value represents the mean of 6-8 rats, except for saline (15-24 rats). *P ⁇ 0.05 and ** P ⁇ 0.01 versus paclitaxel-vehicle treated rats.
compounds of the invention showed activity in the range 0.3 - 10 mg/kg p.o..
compounds of the invention showed activity in the range 0.3 - 10 mg/kg p.o..

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

EP08101879.8A 2008-02-22 2008-02-22 Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques Active EP2098526B1 (fr)

Priority Applications (17)

Application Number	Priority Date	Filing Date	Title
PL08101879T PL2098526T3 (pl)	2008-02-22	2008-02-22	Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu
EP08101879.8A EP2098526B1 (fr)	2008-02-22	2008-02-22	Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques
ES08101879.8T ES2454366T3 (es)	2008-02-22	2008-02-22	Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico
CN200980105813.4A CN101945876B (zh)	2008-02-22	2009-02-17	对慢性疼痛疾病有活性的含氮双环化合物
MX2010009228A MX2010009228A (es)	2008-02-22	2009-02-17	Compuestos biciclicos que contienen nitrogeno que actuan en estados de dolor cronico.
US12/918,718 US8334286B2 (en)	2008-02-22	2009-02-17	Substituted pyrrolo[1,2-A] pyrazines, compositions containing these, processes of making these, and uses thereof
EA201001344A EA017737B1 (ru)	2008-02-22	2009-02-17	Азотсодержащие бициклические соединения, активные при состояниях хронической боли
JP2010547016A JP5400804B2 (ja)	2008-02-22	2009-02-17	慢性痛症に活性のある窒素含有二環式化合物
CA2716230A CA2716230C (fr)	2008-02-22	2009-02-17	Composes bicycliques renfermant de l'azote actifs pour les troubles de douleur chronique
PCT/CH2009/000064 WO2009103176A1 (fr)	2008-02-22	2009-02-17	Composés bicycliques contenant de l'azote agissant sur les états de douleur chronique
BRPI0908495A BRPI0908495A2 (pt)	2008-02-22	2009-02-17	compostos bicíclos contendo nitrogênio ativos em condições de dor crônica
AU2009217201A AU2009217201B2 (en)	2008-02-22	2009-02-17	Nitrogen-containing bycyclic compounds active on chronic pain conditions
CL2009000388A CL2009000388A1 (es)	2008-02-22	2009-02-20	Compuestos derivados de biciclos nitrogenados; proceso de preparacion; composicion farmaceutica; y su uso para tratar el dolor cronico que surge por inflamacion o neuropatia.
ARP090100617A AR070465A1 (es)	2008-02-22	2009-02-20	Compuestos biciclicos con contenido de nitrogeno activos en condiciones de dolor cronicas
PE2009000262A PE20091398A1 (es)	2008-02-22	2009-02-23	Compuestos biciclicos conteniendo nitrogeno activos en condiciones de dolor cronicas
ZA2010/05704A ZA201005704B (en)	2008-02-22	2010-08-10	Nitrogen-containing bycyclic compounds active on chronic pain conditions
IL207669A IL207669A (en)	2008-02-22	2010-08-18	Nitrogen compounds containing nitrogen active in chronic pain states

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP08101879.8A EP2098526B1 (fr)	2008-02-22	2008-02-22	Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11009579 Division-Into		2011-12-05

Publications (2)

Publication Number	Publication Date
EP2098526A1 true EP2098526A1 (fr)	2009-09-09
EP2098526B1 EP2098526B1 (fr)	2014-01-15

Family

ID=39472460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP08101879.8A Active EP2098526B1 (fr)	2008-02-22	2008-02-22	Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques

Country Status (17)

Country	Link
US (1)	US8334286B2 (fr)
EP (1)	EP2098526B1 (fr)
JP (1)	JP5400804B2 (fr)
CN (1)	CN101945876B (fr)
AR (1)	AR070465A1 (fr)
AU (1)	AU2009217201B2 (fr)
BR (1)	BRPI0908495A2 (fr)
CA (1)	CA2716230C (fr)
CL (1)	CL2009000388A1 (fr)
EA (1)	EA017737B1 (fr)
ES (1)	ES2454366T3 (fr)
IL (1)	IL207669A (fr)
MX (1)	MX2010009228A (fr)
PE (1)	PE20091398A1 (fr)
PL (1)	PL2098526T3 (fr)
WO (1)	WO2009103176A1 (fr)
ZA (1)	ZA201005704B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013049174A1 (fr) *	2011-09-29	2013-04-04	Abbvie Inc.	Octahydropyrrolo[1,2-a]pyrazine sulfonamides substitués à titre d'inhibiteurs des canaux calciques
US8669255B2 (en)	2011-09-29	2014-03-11	Abbvie Inc.	Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
US9029361B2 (en)	2012-12-12	2015-05-12	Abbvie Inc.	Agents for treating pain and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9125898B2 (en)	2008-11-14	2015-09-08	Neurotune Ag	Acetam derivatives for pain relief
US8933132B2 (en) *	2011-01-19	2015-01-13	Convergence Pharmaceuticals Limited	Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
LT3114128T (lt)	2014-03-07	2019-03-25	F. Hoffmann-La Roche Ag	Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai
CN107427514B (zh)	2015-03-16	2021-07-13	豪夫迈·罗氏有限公司	使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CA3034185A1 (fr)	2016-09-13	2018-03-22	F. Hoffmann-La Roche Ag	Traitement combine avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hepatite b
JOP20190251A1 (ar)	2017-05-31	2019-10-21	Metys Pharmaceuticals AG	تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
AU2019394706A1 (en) *	2018-12-04	2021-05-20	Metys Pharmaceuticals AG	Synergistic compositions comprising R-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-ones and S-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-ones in a non-racemic ratio
HUE062575T2 (hu)	2018-12-04	2023-11-28	Metys Pharmaceuticals AG	(R)-2-(2-oxopirrolidin-1-il)-butánamidot és (S)-2-(2-oxopirrolidin-1-il)-butánamidot nem-racém arányban tartalmazó szinergetikus kompozíciók
KR102732006B1 (ko)	2019-03-25	2024-11-20	에프. 호프만-라 로슈 아게	Hbv 코어 단백질 알로스테릭 조절제 화합물의 고체 형태

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3225077A (en)	1963-03-05	1965-12-21	American Cyanamid Co	N-cyanoimidates and processes for preparing same
JPH0597819A (ja) *	1990-10-26	1993-04-20	Sankyo Co Ltd	Ｎ−（３，３−ジ置換アクリロイル）ピペラジン誘導体
US5925648A (en)	1997-07-29	1999-07-20	Schering Corporation	Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
EP1118612A1 (fr)	2000-01-21	2001-07-25	Universita Degli Studi di Firenze	Dérivés piperazine ayant une activité nootropique
WO2007037743A1 (fr) *	2005-09-29	2007-04-05	Astrazeneca Ab	Nouveaux composes d'azetidine utiles dans le traitement de troubles gastro-intestinaux fonctionnels, de l'ibs et de la dyspepsie fonctionnelle

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4584990B2 (ja) *	2004-05-18	2010-11-24	シェーリングコーポレイション	Ｐｄｅ４インヒビターとして有用な置換２−キノリル−オキサゾール
AR058805A1 (es) *	2005-09-09	2008-02-27	Smithkline Beecham Corp	Derivados biciclicos de piridina utiles como agentes antipsicoticos

2008
- 2008-02-22 ES ES08101879.8T patent/ES2454366T3/es active Active
- 2008-02-22 PL PL08101879T patent/PL2098526T3/pl unknown
- 2008-02-22 EP EP08101879.8A patent/EP2098526B1/fr active Active
2009
- 2009-02-17 EA EA201001344A patent/EA017737B1/ru not_active IP Right Cessation
- 2009-02-17 CN CN200980105813.4A patent/CN101945876B/zh not_active Expired - Fee Related
- 2009-02-17 US US12/918,718 patent/US8334286B2/en not_active Expired - Fee Related
- 2009-02-17 JP JP2010547016A patent/JP5400804B2/ja active Active
- 2009-02-17 CA CA2716230A patent/CA2716230C/fr active Active
- 2009-02-17 WO PCT/CH2009/000064 patent/WO2009103176A1/fr active Application Filing
- 2009-02-17 MX MX2010009228A patent/MX2010009228A/es active IP Right Grant
- 2009-02-17 AU AU2009217201A patent/AU2009217201B2/en active Active
- 2009-02-17 BR BRPI0908495A patent/BRPI0908495A2/pt not_active IP Right Cessation
- 2009-02-20 AR ARP090100617A patent/AR070465A1/es unknown
- 2009-02-20 CL CL2009000388A patent/CL2009000388A1/es unknown
- 2009-02-23 PE PE2009000262A patent/PE20091398A1/es not_active Application Discontinuation
2010
- 2010-08-10 ZA ZA2010/05704A patent/ZA201005704B/en unknown
- 2010-08-18 IL IL207669A patent/IL207669A/en active IP Right Grant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3225077A (en)	1963-03-05	1965-12-21	American Cyanamid Co	N-cyanoimidates and processes for preparing same
JPH0597819A (ja) *	1990-10-26	1993-04-20	Sankyo Co Ltd	Ｎ−（３，３−ジ置換アクリロイル）ピペラジン誘導体
US5925648A (en)	1997-07-29	1999-07-20	Schering Corporation	Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
EP1118612A1 (fr)	2000-01-21	2001-07-25	Universita Degli Studi di Firenze	Dérivés piperazine ayant une activité nootropique
WO2007037743A1 (fr) *	2005-09-29	2007-04-05	Astrazeneca Ab	Nouveaux composes d'azetidine utiles dans le traitement de troubles gastro-intestinaux fonctionnels, de l'ibs et de la dyspepsie fonctionnelle

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS RHEUM., vol. 43, 2000, pages 1905 - 1915
MANETTI DINA ET AL: "Design, synthesis, and preliminary pharmacological evaluation of 1,4-diazabicyclo(4.3.0)nonan-9-ones as a new class of highly potent nootropic agents", 18 May 2000, JOURNAL OF MEDICINAL CHEMISTRY, VOL. 43, NR. 10, PAGE(S) 1969-1974, ISSN: 0022-2623, XP002488888 *
SCAPECCHI ET AL., BIOORGANIC & MEDICAL CHEMISTRY, vol. 12, 2004, pages 71 - 85
SCAPECCHI SERENA ET AL: "Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs.", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, no. 1, 2 January 2004 (2004-01-02), pages 71 - 85, XP002488886, ISSN: 0968-0896 *
VAN DEN BRANDEN ET AL., J. CHEM. SOC. PERKIN TRANS., vol. 1, 1992, pages 1035 - 1042
VAN DEN BRANDEN S ET AL: "SYNTHESIS OF LACTAM AND KETONE PRECURSORS OF 2 7-SUBSTITUTED OCTAHYDROPYRROLO-1 2-A-PYRAZINES AND OCTAHYDRO-2H-PYRIDO-1 2-A-PYRAZINES", JOURNAL OF THE CHEMICAL SOCIETY PERKIN TRANSACTIONS I, no. 8, 1992, pages 1035 - 1042, XP008094068, ISSN: 0300-922X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013049174A1 (fr) *	2011-09-29	2013-04-04	Abbvie Inc.	Octahydropyrrolo[1,2-a]pyrazine sulfonamides substitués à titre d'inhibiteurs des canaux calciques
US8648074B2 (en)	2011-09-29	2014-02-11	Abbvie Inc.	Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
US8669255B2 (en)	2011-09-29	2014-03-11	Abbvie Inc.	Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
US9029361B2 (en)	2012-12-12	2015-05-12	Abbvie Inc.	Agents for treating pain and uses thereof

Also Published As

Publication number	Publication date
IL207669A (en)	2014-08-31
IL207669A0 (en)	2010-12-30
CL2009000388A1 (es)	2010-02-19
PE20091398A1 (es)	2009-10-13
ZA201005704B (en)	2013-01-30
EA017737B1 (ru)	2013-02-28
JP5400804B2 (ja)	2014-01-29
CN101945876A (zh)	2011-01-12
EA201001344A1 (ru)	2011-02-28
AU2009217201A1 (en)	2009-08-27
BRPI0908495A2 (pt)	2019-09-24
PL2098526T3 (pl)	2014-06-30
ES2454366T3 (es)	2014-04-10
WO2009103176A1 (fr)	2009-08-27
CA2716230A1 (fr)	2009-08-27
CN101945876B (zh)	2014-04-30
MX2010009228A (es)	2010-11-12
US8334286B2 (en)	2012-12-18
JP2011512365A (ja)	2011-04-21
AR070465A1 (es)	2010-04-07
EP2098526B1 (fr)	2014-01-15
CA2716230C (fr)	2016-11-01
AU2009217201B2 (en)	2013-06-20
US20110015200A1 (en)	2011-01-20

Publication	Publication Date	Title
EP2098526B1 (fr)	2014-01-15	Composés bicycliques contenant de l'azote actif pour des conditions de douleurs chroniques
JP7493586B2 (ja)	2024-05-31	Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
JP2022546520A (ja)	2022-11-04	Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
JP6318156B2 (ja)	2018-04-25	キナーゼをモジュレートするための化合物および方法、ならびにその指標
CN105816453B (zh)	2021-03-05	用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
TWI840423B (zh)	2024-05-01	甲狀腺素受體β促效劑化合物
EP3461821A1 (fr)	2019-04-03	Dérivés d'indole carboxamide en tant qu'inhibiteurs de kinase
JP7248256B2 (ja)	2023-03-29	Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
EA024681B1 (ru)	2016-10-31	Имидазопиридины в качестве противовирусных средств против респираторно-синцитиального вируса
EP3131896B1 (fr)	2019-01-30	Inhibiteurs du facteur ixa
US20110082147A1 (en)	2011-04-07	Substituted imidazotriazines
JP7101685B2 (ja)	2022-07-15	新規ｊａｋキナーゼ阻害剤としての二環式アミン
CA3110576A1 (fr)	2020-03-26	Composes destines au traitement de certaines leucemies
EP4079734A1 (fr)	2022-10-26	Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante
JP7009504B2 (ja)	2022-01-25	ヤヌスキナーゼ阻害剤としての新規アミノイミダゾピリジン誘導体及びそれらの医薬としての使用
WO1999043678A1 (fr)	1999-09-02	Medicaments et prophylaxie contre la maladie de parkinson
KR20140113692A (ko)	2014-09-24	전압-게이팅 나트륨 채널 조절제로서의 2-(피리딘-2-일)-1,7-디아자-스피로[4.4]노난-6-온 화합물
CN107344942B (zh)	2020-09-25	调节电压门控钠通道的化合物
IL293191A (en)	2022-07-01	Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
EP3576743B1 (fr)	2023-01-18	Dérivés des acides 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)- 5-azaspiro[2 5]octane-8-carboxyliques comme inhibiteurs de la kinase jak
EP4450497A1 (fr)	2024-10-23	Composé de peptidyle nitrile et son utilisation
JP2024532822A (ja)	2024-09-10	２－芳香族ヘテロ環置換含有ウレア化合物、その製造方法および使用
EP4345101A1 (fr)	2024-04-03	Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2
FR2812636A1 (fr)	2002-02-08	Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones

Legal Events

Date	Code	Title	Description
2009-08-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-09-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2009-09-09	AX	Request for extension of the european patent	Extension state: AL BA MK RS
2009-11-11	17P	Request for examination filed	Effective date: 20090928
2009-12-23	RIN1	Information on inventor provided before grant (corrected)	Inventor name: RONZONI, SILVANO Inventor name: PARINI, CARLO Inventor name: MARTINELLI, MARISA Inventor name: GHELARDINI, CARLA
2010-01-06	17Q	First examination report despatched	Effective date: 20091204
2010-05-12	AKX	Designation fees paid	Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-05-12	AXX	Extension fees paid	Extension state: RS Payment date: 20090928 Extension state: BA Payment date: 20090928 Extension state: AL Payment date: 20090928 Extension state: MK Payment date: 20090928
2013-09-02	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-10-02	INTG	Intention to grant announced	Effective date: 20130903
2013-10-02	RIN1	Information on inventor provided before grant (corrected)	Inventor name: GHELARDINI, CARLA Inventor name: RONZONI, SILVANO Inventor name: MARTINELLI, MARISA Inventor name: PARINI, CARLO
2013-12-06	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2013-12-13	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2013-12-18	RIN1	Information on inventor provided before grant (corrected)	Inventor name: GHELARDINI, CARLA Inventor name: RONZONI, SILVANO Inventor name: MARTINELLI, MARISA Inventor name: PARINI, CARLO
2014-01-15	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2014-01-15	AX	Request for extension of the european patent	Extension state: AL BA MK RS
2014-01-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP
2014-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 649790 Country of ref document: AT Kind code of ref document: T Effective date: 20140215
2014-02-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2014-02-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602008029900 Country of ref document: DE Effective date: 20140227
2014-03-26	REG	Reference to a national code	Ref country code: NL Ref legal event code: T3
2014-04-10	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2454366 Country of ref document: ES Kind code of ref document: T3 Effective date: 20140410
2014-06-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 649790 Country of ref document: AT Kind code of ref document: T Effective date: 20140115
2014-06-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2014-06-30	REG	Reference to a national code	Ref country code: PL Ref legal event code: T3
2014-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140415 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140515
2014-08-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140515 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2014-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2014-10-16	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008029900 Country of ref document: DE
2014-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2014-11-21	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2014-11-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2014-11-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2014-12-03	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2014-12-24	26N	No opposition filed	Effective date: 20141016
2015-01-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222
2015-02-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008029900 Country of ref document: DE Effective date: 20141016
2015-02-19	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8
2015-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2016-02-18	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9
2016-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2016-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2016-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140416
2016-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080222 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115
2017-02-17	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10
2018-02-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11
2023-03-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20230209 Year of fee payment: 16
2023-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20230213 Year of fee payment: 16 Ref country code: ES Payment date: 20230309 Year of fee payment: 16 Ref country code: CH Payment date: 20230303 Year of fee payment: 16
2023-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20230227 Year of fee payment: 16 Ref country code: IT Payment date: 20230210 Year of fee payment: 16 Ref country code: GB Payment date: 20230227 Year of fee payment: 16 Ref country code: DE Payment date: 20230227 Year of fee payment: 16
2024-09-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602008029900 Country of ref document: DE
2024-09-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-10-09	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20240301
2024-10-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229
2024-10-23	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20240222
2024-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229
2024-11-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240301
2024-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240301
2025-01-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240903
2025-01-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240222
2025-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240222 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240903
2025-02-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240222